Novo Nordisk’s Tianjin Insulin Plant Reduces Pollutants By 30%, Above China’s Eco-reduction Targets
This article was originally published in PharmAsia News
Executive Summary
Novo’s new insulin filling plant in Tianjin would more than meet an initial target of a 20% reduction in energy consumption compared to another older, similar facility.
You may also be interested in...
Novo Nordisk Fights Back Dipping Sales In China By Expanding R&D, Manufacturing Capacity
BEIJING - Diabetes-focused Danish firm Novo Nordisk A/S is not deterred by a dip in China sales, and is planning to expand its R&D center and manufacturing capability in China to maintain its leading position in the country
China’s Simcere Receives Buyout Offer From Its Chairman, But Could Delisting Be A Negative Overseas?
Simcere would join Chinese firms 3SBio and ShangPharma in pulling out of the U.S. stock market.
China’s New Good Supply Practices Regs Require Electronic Barcodes; Raise Bar To Entry
The Ministry of Health’s GSP regulation tries to plug a hole in supply chain security through tighter IT controls, such as requiring electronic barcodes.